News
QTTB
13.17
+10.21%
1.22
Health Care had the best week vs. the S&P 500 on record
Seeking Alpha · 2d ago
Q32 Bio files $300M mixed securities shelf
TipRanks · 3d ago
Q32 Bio Files Prospectus For $300M Offering
Benzinga · 3d ago
Q32 BIO - MAY OFFER UP TO $300 MLN IN SECURITIES - SEC FILING
Reuters · 3d ago
Five new option listings and two option delistings on June 24th
TipRanks · 4d ago
Weekly Report: what happened at QTTB last week (0615-0619)?
Weekly Report · 6d ago
Q32 Bio Shareholders Back Directors, Auditor and Executive Pay
TipRanks · 06/16 21:01
Q32 Bio shareholders elected Class II directors at annual meeting
PUBT · 06/16 20:02
Weekly Report: what happened at QTTB last week (0608-0612)?
Weekly Report · 06/15 09:32
Hansa Biopharma names Adam Cutler CFO, effective June 22
PUBT · 06/15 05:01
Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK
Seeking Alpha · 06/09 09:18
Weekly Report: what happened at QTTB last week (0601-0605)?
Weekly Report · 06/08 09:30
Thursday Sector Leaders: Advertising, Biotechnology Stocks
NASDAQ · 06/04 16:56
Q32 Bio director and 10% owner Diyong Xu acquires $15 million in common shares
PUBT · 06/02 01:16
OrbiMed Advisors acquires Q32 Bio common shares worth $15 million in private placement
PUBT · 06/02 01:13
Weekly Report: what happened at QTTB last week (0525-0529)?
Weekly Report · 06/01 09:32
Why Is Q32 Bio Stock Gaining Friday?
Benzinga · 05/29 14:10
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 05/28 17:05
3 Penny Stocks to Watch Now, 5/28/26
TipRanks · 05/28 15:22
Q32 Bio: "Buy" On Bempikibart Advancement And Mid-2026 Data Catalysts
Seeking Alpha · 05/28 13:18
More
Webull provides a variety of real-time QTTB stock news. You can receive the latest news about Q32 BIO INC through multiple platforms. This information may help you make smarter investment decisions.
About QTTB
Q32 Bio Inc. is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing therapies for alopecia areata and other autoimmune and inflammatory diseases. The Company is advancing bempikibart (ADX-914), a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Additional discovery and earlier development efforts from its complement inhibitor platform include ADX-096, a C3d mAb – CR1 fusion protein with preclinical data supportive of its use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition.